https://www.bloomberg.com/news/articles/2023-03-12/svb-research-unit-expects-business-to-continue-as-normal?sref=y3YMCJ4e&leadSource=uverify%20wall
BioAtla Provides Clinical Program Updates And Upcoming 2023 Milestones
Clinical Program Updates
Phase 2 Trial of Mecbotamab Vedotin (BA3011, NCT03425279) in Patients with:
AXL-positive NSCLC
Part 1 of the trial ongoing in patients who have previously experienced failure of